Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab170548-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $89.90 | |
| Ab170548-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $429.90 | |
| Ab170548-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $837.90 | |
| Ab170548-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,254.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Brentuximab (anti-TNFRSF8) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to TNFRSF8, >95%, high purity, Human IgG1 |
|---|---|
| Synonyms | Brentuximab; CD 30 antibody; CD30 antibody; CD30 antigen antibody; CD30L receptor antibody; Cytokine receptor CD30 antibody; D1S166E antibody; KI 1 antibody; KI 1 antigenantibody; Ki-1 antigen antibody; KI1 antibody; Lymphocyte activation antigen CD30 ant |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | TNFRSF8 |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description | Brentuximab (anti-TNFRSF8) is a chimeric antibody targeting CD30. Brentuximab can be used for the research of emerging targeted therapies. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| Light Chain Type | kappa |
| SDS-PAGE | 28.0 kDa (Light Chain) & 51.5 kDa (Heavy Chain), under reducing conditions; 172.2 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 2088770-90-3 |
Brentuximab (anti-TNFRSF8) (Ab170548) - Flow Cytometry
Flow Cytometry analysis of Jurkat cells labelling TNFRSF8 (red) with Brentuximab (anti-TNFRSF8) (Ab170548). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Brentuximab (anti-TNFRSF8) (Ab170548) - SEC
The purity of Brentuximab (anti-TNFRSF8) (Ab170548) is more than 95% verified by HPLC.
Brentuximab (anti-TNFRSF8) (Ab170548) - ELISA
Immobilized huCD30-his 2 μg/mL can bind Brentuximab (anti-TNFRSF8) (Ab170548) with the EC₅₀ of 6.00 ng/mL.
Brentuximab (anti-TNFRSF8) (Ab170548) - ELISA
Immobilized Recombinant Human CD30 Protein (rp169577) at 1.0 μg/mL can bind Brentuximab (anti-TNFRSF8) (Ab170548) with the EC50 of 119.9 ng/mL.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F0800942 | Certificate of Analysis | Aug 30, 2023 | Ab170548 |
| ZJ23F0800938 | Certificate of Analysis | Aug 30, 2023 | Ab170548 |
| 1. Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, Knackmuss SH, Kiprijanov S, Little M, Zhukovsky EA. (2014) A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.. MAbs, 6 (3): (728-39). [PMID:24670809] |
| 2. Dürkop, H H and 5 more authors.. (1992) Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.. Cell, (7): [PMID:1310894] |
| 3. Jung, W W and 6 more authors.. (1994) Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources.. Molecular immunology, [PMID:7527901] |
| 4. Smith, C A CA and 9 more authors.. (1993) CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.. Cell, (2): [PMID:8391931] |
| 5. Lee, S Y SY, Park, C G CG and Choi, Y Y.. (1996) T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors.. The Journal of experimental medicine, (1): [PMID:8627180] |
| 6. Horie, R R and 9 more authors.. (1996) A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages.. Blood, (1): [PMID:8839832] |
| 7. Aizawa, S S and 9 more authors.. (1997) Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation.. The Journal of biological chemistry, (24): [PMID:8999898] |
| 8. Boucher, L M LM, Marengère, L E LE, Lu, Y Y, Thukral, S S and Mak, T W TW.. (1997) Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily.. Biochemical and biophysical research communications, (28): [PMID:9168896] |
| 9. Mizushima, S S and 8 more authors.. (1998) Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5).. Gene, (30): [PMID:9511754] |
| 10. Francisco, Joseph A JA and 14 more authors.. (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.. Blood, (15): [PMID:12714494] |
